Increasepharm (Tianjin) Institute Co., Ltd

Founded in March 2018, Increasepharm (Tianjin) Institute Co., Ltd is a wholly-owned subsidiary of Beijing Increasepharm Corporation Limited, Tianjin Company is a state-level high-tech enterprise and a national-level technology-based small and medium-sized enterprise. It has won the second collective prize of Golden Bridge Award of China Technology Market Association.

The company is located in Hengtong Enterprise Port, Xiqing District, Tianjin, with a total area more than 8,000 m2, laboratory area exceeds 5,000 m2. The company has more than 200 employees, half of which are masters and doctors and associate senior titles, forming a high-quality scientific and technological R&D team led by doctoral supervisors and professors.

The company consists of TCM new drug R&D Center, TCM raw material Research Center, Preparation Research Center, API Research Center, Technology Management Center, Analysis Center, Support Center and Ministry of Commerce, and other departments; Business scope covers chemical and TCM R&D.

Tianjin Company is a key R&D enterprise among the 10 subsidiaries of Increasepharm. The full chain R&D system covering project initiation and approval, preclinical research, clinical research, registration application and industrialization, it focuses on preclinical CRO service for TCM and chemical medicine. The company has established long-term and stable industry-university-research cooperation relationships with Nankai University, Hong Kong Polytechnic University, Hong Kong Baptist University, Tianjin University of Traditional Chinese Medicine, Tianjin Pharmaceutical Research Institute and other universities and research institutes; It has established long-term strategic partnership with well-known domestic pharmaceutical companies such as Tasly Group, Shenwei Pharmaceutical, Yiling Pharmaceutical  and Otsuka Pharmaceuticals. Undertook 4 provincial and municipal projects such as major projects of Ministry of Science and Technology of the People's Republic of China, G20 engineering pharmaceutical industry innovation research and development, and national strategic scientific and technological innovation cooperation key projects; has applied for 63 invention patents, 1 PCT application, 17 authorized patents and 16 registered trademarks items. 3 clinical permission and 10 manufacturing license have been obtained.

After years of development, the company has received assistance from municipal, district and town governments and officer leaders at all levels, and has achieved innovative development of the company through "internal management, external market expansion" and technology research and development as the driving force.